MX389449B - Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. - Google Patents
Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.Info
- Publication number
- MX389449B MX389449B MX2020004724A MX2020004724A MX389449B MX 389449 B MX389449 B MX 389449B MX 2020004724 A MX2020004724 A MX 2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A MX 389449 B MX389449 B MX 389449B
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- inh
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 title 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791399P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030309 WO2014145519A2 (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020004724A MX2020004724A (es) | 2022-01-18 |
| MX389449B true MX389449B (es) | 2025-03-20 |
Family
ID=51538486
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004724A MX389449B (es) | 2013-03-15 | 2014-03-17 | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
| MX2015011281A MX373965B (es) | 2013-03-15 | 2014-03-17 | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). |
| MX2021011946A MX2021011946A (es) | 2013-03-15 | 2015-08-28 | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011281A MX373965B (es) | 2013-03-15 | 2014-03-17 | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). |
| MX2021011946A MX2021011946A (es) | 2013-03-15 | 2015-08-28 | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US9616111B2 (enExample) |
| EP (3) | EP3290046B1 (enExample) |
| JP (9) | JP6184581B2 (enExample) |
| KR (4) | KR20150135242A (enExample) |
| CN (2) | CN111529708A (enExample) |
| AU (3) | AU2014232912A1 (enExample) |
| BR (1) | BR112015023207A8 (enExample) |
| CA (2) | CA2904543C (enExample) |
| CY (2) | CY1119419T1 (enExample) |
| DE (1) | DE202014011208U1 (enExample) |
| DK (2) | DK3290046T3 (enExample) |
| EA (1) | EA201591278A1 (enExample) |
| ES (2) | ES2713004T3 (enExample) |
| GB (1) | GB2530921B (enExample) |
| HK (1) | HK1250912B (enExample) |
| HR (2) | HRP20171269T1 (enExample) |
| HU (2) | HUE041837T2 (enExample) |
| IL (2) | IL241549B (enExample) |
| LT (2) | LT3290046T (enExample) |
| ME (2) | ME02865B (enExample) |
| MX (3) | MX389449B (enExample) |
| PL (2) | PL2968434T3 (enExample) |
| PT (2) | PT2968434T (enExample) |
| RS (2) | RS58351B1 (enExample) |
| SG (2) | SG10201707598QA (enExample) |
| SI (2) | SI3290046T1 (enExample) |
| SM (2) | SMT201700415T1 (enExample) |
| TR (1) | TR201900319T4 (enExample) |
| WO (1) | WO2014145519A2 (enExample) |
| ZA (3) | ZA201507604B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6184581B2 (ja) | 2013-03-15 | 2017-08-23 | シャイア バイロファーマ インコーポレイテッド | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| KR102312817B1 (ko) | 2013-11-22 | 2021-10-13 | 다케다 야쿠힌 고교 가부시키가이샤 | C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법 |
| MX2017010323A (es) * | 2015-02-20 | 2017-12-07 | Csl Behring Gmbh | Formulaciones farmaceuticas de inhibidor de esterasa c1. |
| CN108025047B (zh) * | 2015-05-28 | 2021-11-19 | 康奈尔大学 | 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法 |
| EP3377093B1 (en) | 2015-11-19 | 2022-07-13 | Takeda Pharmaceutical Company Limited | Recombinant human c1 esterase inhibitor and uses thereof |
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| JP2019534240A (ja) * | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
| US12083171B2 (en) | 2017-05-16 | 2024-09-10 | Octapharma Ag | C1-esterase inhibitor preparation |
| KR20210005549A (ko) | 2018-02-28 | 2021-01-14 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 전자간증의 치료 및 예방 |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| US12397054B2 (en) | 2018-06-22 | 2025-08-26 | Junten Bio Co., Ltd. | Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte |
| TWI854983B (zh) | 2018-06-22 | 2024-09-11 | 日商順天生化股份有限公司 | 誘導免疫耐受之抗體、被誘導之淋巴球、及使用被誘導之淋巴球之細胞治療劑治療方法 |
| TWI832868B (zh) | 2018-06-22 | 2024-02-21 | 日商順天生化股份有限公司 | 用於誘發感染性免疫耐受之組合物 |
| WO2021124793A1 (ja) * | 2019-12-16 | 2021-06-24 | ニプロ株式会社 | 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| US20240342258A1 (en) | 2021-07-09 | 2024-10-17 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
| WO2025090843A1 (en) * | 2023-10-27 | 2025-05-01 | Kansas State University Research Foundation | Small-molecule inhibitors of c1s protease and classical complement pathway |
| CN119823254B (zh) * | 2025-03-14 | 2025-06-03 | 深圳市卫光生物制品股份有限公司 | 一种c1酯酶抑制剂重组变体及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| EP0716611B1 (en) | 1993-09-01 | 2002-02-06 | Stichting Sanquin Bloedvoorziening | C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction |
| EP0868191A1 (en) | 1995-12-18 | 1998-10-07 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
| AT409336B (de) | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
| WO2001057079A2 (en) | 2000-01-31 | 2001-08-09 | Pharming Intellectual Property B.V. | C1 inhibitor produced in the milk of transgenic mammals |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| ATE442862T2 (de) | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| WO2004034971A2 (en) | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| USRE43691E1 (en) | 2003-05-16 | 2012-09-25 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
| US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| EP2529746A1 (en) | 2005-06-06 | 2012-12-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of reperfusion injury |
| CN101340928B (zh) | 2005-10-21 | 2011-12-21 | 催化剂生物科学公司 | 抑制补体激活的修饰的蛋白酶 |
| CN105641688B (zh) * | 2005-12-21 | 2020-06-09 | 法明知识产权股份有限公司 | C1抑制剂在预防缺血-再灌注损伤中的应用 |
| NZ568749A (en) | 2005-12-21 | 2011-05-27 | Pharming Intellectual Pty Bv | Use of C1 inhibitor with reduced terminal sialic residues for the prevention of ischemia-reperfusion injury |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| DK2109457T3 (en) | 2007-02-12 | 2016-04-11 | Csl Behring Gmbh | THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS |
| NZ585702A (en) | 2007-11-30 | 2013-08-30 | Abbott Lab | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| RS20120461A1 (sr) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | Metode za stimulaciju regeneracije jetre |
| JP5911804B2 (ja) | 2009-10-16 | 2016-04-27 | オメロス コーポレーション | Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法 |
| US9815876B2 (en) | 2010-03-05 | 2017-11-14 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| WO2011116291A1 (en) * | 2010-03-18 | 2011-09-22 | Thrombolytic Science International | Production of human c1 inhibitor in human cells |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| WO2013041677A1 (en) | 2011-09-24 | 2013-03-28 | Csl Behring Gmbh | Combination therapy using immunoglobulin and c1-inhibitor |
| WO2013093027A1 (en) * | 2011-12-22 | 2013-06-27 | Csl Behring Gmbh | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| EP2825204A1 (en) | 2012-03-16 | 2015-01-21 | Belrose Pharma Inc. | Polymeric conjugates of c-1 inhibitors |
| CA2902841A1 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| JP6184581B2 (ja) * | 2013-03-15 | 2017-08-23 | シャイア バイロファーマ インコーポレイテッド | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP6889626B2 (ja) * | 2017-06-29 | 2021-06-18 | トキコシステムソリューションズ株式会社 | 燃料供給システム |
| JP6935245B2 (ja) * | 2017-06-29 | 2021-09-15 | 大和ハウス工業株式会社 | 収容ラック |
-
2014
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 MX MX2020004724A patent/MX389449B/es unknown
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko not_active Ceased
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en not_active Withdrawn
- 2014-03-17 SM SM20170415T patent/SMT201700415T1/it unknown
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active Ceased
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active Active
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active Active
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 SM SM20190141T patent/SMT201900141T1/it unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 MX MX2015011281A patent/MX373965B/es active IP Right Grant
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en not_active Ceased
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
-
2018
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/en unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389449B (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001368A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2017003142A1 (es) | Composiciones que comprenden cepas bacterianas | |
| PE20180243A1 (es) | Composiciones que comprenden cepas bacterianas | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| MX2017006043A (es) | Metodo y composiciones de anti-hcmv. | |
| AR106769A1 (es) | Composiciones que comprenden cepas bacterianas | |
| MX2016010967A (es) | Nuevas composiciones para tratar lesiones neuronales mecanicas. | |
| BR112018007290A2 (pt) | minha patente 1 |